Poor outcomes after Tpoxx mpox treatment mainly seen in those with weak immunity
Tecovirimat prescribed to over 7,100 US mpox patients (2022-2023) for rash and pain, with most SAEs in immune-compromised patients. Skin and anogenital regions most affected. 223 SAEs (3.1%) and 40 deaths (0.6%) reported, mainly in severely immunocompromised. HIV patients with low CD4 counts had poor outcomes. EA-IND data insufficient; controlled trials needed.
Reference News
Poor outcomes after Tpoxx mpox treatment mainly seen in those with weak immunity
Tecovirimat prescribed to over 7,100 US mpox patients (2022-2023) for rash and pain, with most SAEs in immune-compromised patients. Skin and anogenital regions most affected. 223 SAEs (3.1%) and 40 deaths (0.6%) reported, mainly in severely immunocompromised. HIV patients with low CD4 counts had poor outcomes. EA-IND data insufficient; controlled trials needed.